351. Eight Years of Growth Hormone Treatment in Children With Prader-Willi Syndrome
- Author
-
E. Van Pinxteren-Nagler, van Maria Leeuwen, Danny A. J. P. Haring, Joost Rotteveel, H. Van Wieringen, R. J. Odink, M. A. J. de Ridder, J. J. G. Hoorweg-Nijman, N. E. Bakker, A. A. E. M. Van Alfen, Gianni Bocca, G. C. B. (Karen) Bindels-de Heus, Rene C. F. M. Vreuls, E J Schroor, Dederieke A. M. Festen, Nitash Zwaveling-Soonawala, R. J. Kuppens, Euphemia C. A. M. Houdijk, L. Lunshof, Elbrich P. C. Siemensma, R. F. A. Tummers-de Lind van Wijngaarden, Anita C. S. Hokken-Koelega, Petr E. Jira, Wilma Oostdijk, Pediatric surgery, ICaR - Circulation and metabolism, Faculteit Medische Wetenschappen/UMCG, Pediatrics, Psychiatry, Epidemiology, APH - Amsterdam Public Health, Obstetrics and Gynaecology, Other Research, and Paediatric Endocrinology
- Subjects
Male ,medicine.medical_specialty ,BODY-COMPOSITION ,Adolescent ,DISORDERS ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,CHILDHOOD ,METABOLISM ,Biochemistry ,THERAPY ,law.invention ,Absorptiometry, Photon ,Endocrinology ,Randomized controlled trial ,Bone Density ,law ,Internal medicine ,ADOLESCENTS ,Humans ,Medicine ,Obesity ,Prospective Studies ,Child ,Prospective cohort study ,Human Growth Hormone ,business.industry ,Biochemistry (medical) ,RANDOMIZED CONTROLLED-TRIAL ,medicine.disease ,Body Height ,PREVALENCE ,Growth hormone treatment ,DEFICIENCY ,Somatropin ,Treatment Outcome ,Blood pressure ,Child, Preschool ,Body Composition ,Disease Progression ,Lean body mass ,RISK-FACTORS ,Female ,business ,Prader-Willi Syndrome ,Body mass index - Abstract
Background: The most important reason for treating children with Prader-Willi syndrome (PWS) with GH is to optimize their body composition.Objectives: The aim of this ongoing study was to determine whether long-term GH treatment can counteract the clinical course of increasing obesity in PWS by maintaining the improved body composition brought during early treatment.Setting: This was a multicenter prospective cohort study.Methods: We have been following 60 prepubertal children for 8 years of continuous GH treatment (1 mg/m(2)/d congruent to 0.035 mg/kg/d) and used the same dual-energy x-ray absorptiometry machine for annual measurements of lean body mass and percent fat.Results: After a significant increase during the first year of GH treatment (P Conclusion: This 8-year study demonstrates that GH treatment is a potent force for counteracting the clinical course of obesity in children with PWS.
- Published
- 2013